RE: News outThis is HUGE news, even better then I had expected. Dr. Vanderhyden is one of the most respected oncologists in the field of Ovarian cancer and for her to say " We are very pleased that the data CLEARLY show an impact of this peptide on some of our most aggressive ovarian cancer cell lines." is huge for PharmaGap. Now I know why OHRI is moving ahead with further studies. PharmaGap's drug seems to working where all other Ovarian cancer drugs are not. This news is not only great for the investor but also for many women who in the future may find themselves with this extreme cancer......